5d 1m 3m 1y 5y 10y
There are no Transcripts on BIS.
There are no News articles on BIS.
BIS vs. ETF Alternatives
ProShares UltraShort Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to twice (200%) the inverse (opposite) of the daily performance of the NASDAQ Biotechnology® Index.
See more details on sponsor's website
See more details on sponsor's website
Tuesday, Jan 289:12 AM
Tuesday, Jan 289:12 AM| Comment!
- Deutsche's Robyn Karnauskas makes a big call on big-cap biotechs, boosting price targets for Biogen (BIIB) to $415 from $340, Celgene (CELG) to $190 from $170, and Gilead (GILD) to $132 from $95. The $132 PT for Gilead is a new Street high "by a nautical mile," says Notable Calls, and Karnauskas sees upside all the way to $165.
- "We view large-cap biotech as fundamentally stable yet providing attractive growth," she writes, citing more diversified businesses, pipelines, new product launches, strong balance sheets, and strong free cash flow. "Therefore, we are changing our valuation methodology to 2015 PE multiples from DCF for Gilead, Celgene, and Biogen. Our '15 EPS estimates are higher than consensus and we think near-term franchise success could drive re-rating."
- GILD +2.7%, CELG +1.3% premarket
- Related ETFs: IBB, XBI, BIB, BBH, FBT, PBE, BIS
Monday, Jan 2710:52 AM
Monday, Jan 2710:52 AM| 23 Comments
- A little bit more air comes out of the previously scorching small-cap biotech names today. Among them: CytRx (CYTR -4.8%), Dyax (DYAX -5.2%), Galena (GALE -9.6%), Novavax (NVAX -9%), Arena (ARNA -6.3%), Synta (SNTA -10.8%), Zogenix (ZGNX -3.5%), Tonix (TNXP -8.4%).
- Biotech ETFs: IBB, XBI, BIB, BBH, FBT, PBE, BIS
Thursday, Oct 102013, 11:57 AM
Thursday, Oct 102013, 11:57 AM| Comment!
- Biotechs took a beating in the first three days of this week but they're rallying today, so investors need to decide whether they should be using the dip to buy or the bounce to sell.
- Citi sees a mixed view for the sector: Given the scarcity of growth stocks in the overall market, the firm expects large-cap biotechs to bounce back but is far less sanguine about small- and mid-caps where valuations are broadly stretched and the Street is overly optimistic of the chances for pipeline success.
- The firm's favorites include Gilead (GILD +4.7%) and Celgene (CELG +3.5%), and sees compelling risk/reward in Medivation (MDVN +3.9%) and Tesaro (TSRO +5.7%).
- ETFs: IBB, XBI, FBT, PBE, BBH, BIB, BIS.
Thursday, Sep 262013, 10:43 AM
Thursday, Sep 262013, 10:43 AM| Comment!
- Cramer says biotech is a safe haven amid the uncertainty emanating from Washington, as pipelines are strong and the sector is not sensitive to the trajectory of the overall economy — this is a "double advantage", he says.
- Celldex (CLDX +5.3%) — which is part of this week's billion dollar biotech price target bump club courtesy of Leerink and Cantor — gets a glowing recommendation as Cramer calls the company "just incredible."
- Other companies getting a name drop: Celgene (CELG +2.4%), Immunogen (IMGN +2%), and Onyx (ONXX).
- ETFs - IBB, XBI, FBT, PBE, BBH, BIB, BIS
Monday, Mar 122012, 12:07 PMShares of Anthera Pharmaceuticals (ANTH -52.1%) can't stop the freefall that was triggered by Friday's announcement that it's canceling its late-stage trial of its experimental treatment for heart disease. Adam Feuerstein eyes the recent carnage with a number of biotech names to conclude that "fail" is now re-entering the lexicon of investors in the sector. |Monday, Mar 122012, 12:07 PM| Comment!
Thursday, Aug 42011, 4:05 PMDendreon (DNDN -67.4%) takes down an entire industry, with the Amex Biotech index falling an astonishing 10.4%. "Biotech risk takers burned on this one might be less risk tolerant going forward," one analyst explains. "The biotech group does work like that, especially for product failures." IBB -7.9%. XBI -9.8%. |Thursday, Aug 42011, 4:05 PM| Comment!
- View all 2 replies
Justin M. Hall:: I first highlighted the bifurcarted market theme on 3/8/12. Others are beginning to catch on. :-)
- View all 5 replies
Justin M. Hall:: [BIS] Going forward, I firmly believe it'll prove to be a solid bet. So, let's see how it plays out.